<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0407210840
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VESICARE 10 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SOLIFENACIN SUCCINATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        174.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BD08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance of Vesicare belongs to the group of anticholinergics.</p><p>These medicines are used to reduce the activity of an overactive bladder.</p><p>This enables you to wait longer before having to go to the bathroom and increases the amount of urine that can be held by your bladder.</p><p>Vesicare is used to treat the symptoms of a condition caled overactive bladder.</p><p>These symptoms include: having a strong, sudden urge to urinate without prior warning, having to urinate frequently or wetting yourself because you could not get to the bathroom in time.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Vesicare</strong></p><p>&minus; if you have an inability to pass water or to empty your bladder completely (urinary retention)</p><p>&minus; if you have a severe stomach or bowel condition (including toxic megacolon, a complication associated with ulcerative colitis)</p><p>&minus; if you suffer from the muscle disease called myasthenia gravis, which can cause an extreme weakness of certain muscles</p><p>&minus; if you suffer from increased pressure in the eyes, with gradual loss of eye sight (glaucoma)</p><p>&minus; if you are allergic (hypersensitive) to solifenacin or any of the other ingredients of Vesicare</p><p>&minus; if you are undergoing kidney dialysis</p><p>&minus; if you have severe liver disease</p><p>&minus; if you suffer from severe kidney disease or moderate liver disease AND at the same time are being treated with medicines that may decrease the removal of Vesicare from the body (for example, ketoconazole). Your doctor or pharmacist will have informed you if this is the case.</p><p>Inform your doctor if you have or ever had any of the above mentioned conditions before treatment with Vesicare starts.</p><p><strong>Take special care with Vesicare</strong></p><p>&minus; if you have trouble emptying your bladder (= bladder obstruction) or have difficulty in passing urine (e.g. a thin urine flow). Risk of accumulation of urine in the bladder (urinary retention) is much higher.</p><p>&minus; if you have some obstruction of the digestive system (constipation).</p><p>&minus; if you are at risk of your digestive system slowing down (stomach and</p><p>bowel movements). Your doctor will have informed you if this is the case.</p><p>&minus; if you suffer from severe kidney disease.</p><p>&minus; if you have moderate liver disease.</p><p>&minus; if you have a stomach tear (hiatus hernia) or heartburn.</p><p>&minus; if you have a nervous disorder (autonomic neuropathy).</p><p><strong>Vesicare is not to be used in children or adolescents under 18 years.</strong></p><p>Inform your doctor if you have or ever had any of the above mentioned conditions before treatment with Vesicare starts. Angioedema (skin allergy that results in the swelling that occurs in the tissue just below the surface of the skin) with airway obstruction (difficulty in breathing) has been reported in some patients on solifenacin succinate(Vesicare). If angioedema occurs, solifenacin succinate (Vesicare) should be discontinued immediately and appropriate therapy and/or measures should be taken. Before starting Vesicare, your doctor will assess whether there are other causes for your need to pass urine frequently (for example heart failure (insufficient pumping power of the heart) or kidney disease). If you have a urinary tract infection, your doctor will prescribe you an antibiotic (a treatment against particular bacterial infections).</p><p><strong>Taking other medicines</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a</p><p>prescription.</p><p>It is especially important to inform your doctor if you are taking:</p><p>- other anticholinergic medicines, effects and side effects of both medications can be enhanced.</p><p>- cholinergics as they can reduce the effect of Vesicare.</p><p>- medicines, like metoclopramide and cisapride, which make the digestive system work faster. Vesicare can reduce their effect.</p><p>- medicines, like ketoconazole, ritonavir, nelfinavir, intraconazole, verapamil and diltiazem, which decrease the rate at which Vesicare is broken down by the body</p><p>- medicines like rifampicin, phenytoin and carbamazepine, as they may increase the rate at which Vesicare is broken down by the body.</p><p>- medicines such as bisphosphonates, that can cause or exacerbate inflammation of the gullet (oesophagitis).</p><p><strong>Taking Vesicare with food and drink</strong></p><p>Vesicare can be taken with or without food, depending on your preference.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>You should not use Vesicare if you are pregnant unless clearly necessary.</p><p>Do not use Vesicare if you are breast-feedding as solifenacin may get into</p><p>your breast milk.</p><p>Ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>Vesicare may cause blurred vision and sometimes sleepiness or tiredness.</p><p>If you suffer from any of these side effects, do not drive or operate machinery.</p><p><strong>Important information about some of the ingredients of Vesicare</strong></p><p>Vesicare contains lactose. If you have been told by your doctor that you have a rare hereditary problem of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption you should not use this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Instructions for proper use</strong></p><p>Always take Vesicare exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>You should swallow the whole tablet with some liquid. It can be taken with or without food, according to your preference. Do not crush the tablets.</p><p>The usual dose is 5 mg per day, unless your doctor told you to take 10 mg per day.</p><p><strong>If you take more Vesicare than you should</strong></p><p>If you have taken too much Vesicare or if a child has accidentally taken Vesicare, contact your doctor or pharmacist immediately.</p><p>Symptoms of overdose may include: headache, dry mouth, dizziness, drowsiness and blurred vision, perceiving things that are not there (hallucinations), over- excitability, seizures (convulsions), difficulty breathing, elevated heart rate (tachycardia), accumulation of urine in the</p><p>bladder (urinary retention) and dilated pupils (mydriasis).</p><p><strong>If you forget to take Vesicare</strong></p><p>If you forget to take a dose at the usual time, take it as soon as you remember, unless it is time to take your next dose. Never take more than one dose per day. If you are in doubt, always consult your doctor or pharmacist.</p><p><strong>If you stop taking Vesicare</strong></p><p>If you stop taking Vesicare, your symptoms of overactive bladder may return or worsen. Always consult your doctor, if you are considering stopping the treatment.</p><p><strong>If you have any further questions on the use of this product, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Vesicare can cause side effects, although not everybody gets them.</p><p>Vesicare may cause the following:</p><p><strong>Very common side effects (likely to affect more than 1 in 10 patients)</strong><br />- dry mouth<br /><strong>Common side effects (likely to affect more than 1 in 100 and less than 1 in 10 patients)</strong></p><p>- blurred vision</p><p>- constipation, nausea, indigestion with symptoms such as a abdominal fullness, abdominal pain, burping, nausea, and heartburn (dyspepsia),</p><p>stomach discomfort.</p><p><strong>Uncommon side effects (likely to affect more than 1 in 1000 and less than 1 in 100 patients)</strong></p><p>- urinary tract infection, bladder infection</p><p>- sleepiness,</p><p>- impaired sense of taste (dysgeusia)</p><p>- dry (irritated) eyes</p><p>- dry nasal passages</p><p>- reflux disease (gastro-oesophageal reflux),</p><p>- dry throat</p><p>- dry skin</p><p>- difficulty in passing urine</p><p>- tiredness,</p><p>- accumulation of fluid in the lower legs (oedema)</p><p><strong>Rare side effects (likely to affect more than 1 in 10,000 and less than 1 in 1000 patients)</strong></p><p>- lodging of a large amount of hardened stool in the large intestine (faecal impaction)</p><p>- build up of urine in the bladder due to inability to empty the bladder (urinary retention)</p><p>- dizziness, headache</p><p>- vomiting</p><p>- itching, rash,</p><p><strong>Very rare side effects (likely to affect less than 1 in 10,000 patients)</strong></p><p>- hallucinations, confusion</p><p>- changes in the electrical activity of the heart (ecg), irregular heartbeat (torsade de pointes)</p><p>- allergic rash</p><p>- skin allergy that results in the swelling that occurs in the tissue just below the surface of the skin (angioedema)</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>&bull;decreased appetite, high levels of blood potassium which can cause abnormal heart rhythm</p><p>&bull;increased pressure in the eyes</p><p>&bull;changes in the electrical activity of the heart (ecg), irregular heartbeat, feeling your heartbeat, faster heart beat</p><p>&bull;voice disorder</p><p>&bull;liver disorder</p><p>&bull;muscle weakness</p><p>&bull;renal disorder</p><p><strong>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Store below 30&deg;c.</p><p>Do not use vesicare after the expiry date which is stated on the carton after exp. The expiry date refers to the last day of that month.</p><p>Medicines should not be disposed of via wastewater or household waste.</p><p>Ask your pharmacist how to dispose of medicines no longer required.</p><p>These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; the active substance is solifenacin succinate 5 mg</p><p>&bull; the other ingredients are maize starch, lactose monohydrate,</p><p>hypromellose, magnesium stearate and opadry yellow</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vesicare 5 mg tablets are round, light pink film coated tablet, coded by SJ 233 on one side and plain on the other side.
Packs of 30 film coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA pharmaceuticals<br />Saudi Arabian Japanese pharmaceutical company limited<br />Jeddah &ndash; Saudi Arabia<br />Under license from<br />Astellas Pharma inc.<br />Tokyo-japan</p><p><strong>To report any side effect(s)</strong><br /><strong><strong>&bull; Saudi Arabia</strong></strong><br />- The National Pharmacovigilance Centre (NP):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa<br /><strong><strong>&bull; Other GCC states /other countries</strong></strong><br />-Please contact the relevant competent authority.</p><p><strong>&bull; United Arab Emirates</strong><br />Pharmacovigilance &amp; Medical Device section<br />P.O.Box: 1853<br />Tel: 80011111<br />Email : pv@mohap.gov.ae<br />Drug Department<br />Ministry of Health &amp; Prevention<br />Dubai - UAE<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تنتمي المادة الفعالة لـ &quot;فيزيكير&quot; الى مجموعة ُمضاَّدات الكولينيات. تُستخدم هذه الأدوية لِلحد ِمن فرط نشاط المثانة. وهذه الادوية تُعطيك القدرة على الانتظار لفترة أطول َقبل أن تَضطر للذهاب إلى المرحاض كما تَزيد من كمية البول التي تَستَطيع المثانُة الاحتفاظ بها يُستخدم فيزيكير لعلاج أعراِض حالة تُعرف بـ &ldquo;فرط نشاط المثانة&quot;.&nbsp; تَشمل هذه الأعراض: إلحاح ُمفاجئ للتبول بدون سابق إنذار، الحاجة للتبول بِشكل ُمتَكرر، أو تُصبح مبللا (تبول لا إرادي)؛ لأنك لم تَستَطع الوصول إلى الحمام في الوقت المناسب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تناول فيزيكير:</p><p>- إذا كنت تعاني من َعدم القدرة على التبول أو لا تَستَطيع إفراغ المثانة بالكامل (احتباس البول)</p><p>- إذا كنت تعاني من َحالَة َشديدة في المعدة أو الأمعاء (بما في ذلك تَضخم القولون السمي وهو من المضاعفات المصاحبة لاتهاب القولون التقرحي).</p><p>- إذا كنت تعاني ِمن َمرض َعضلِي يُعرف بـ &ldquo;الوهن العضلِي الوبيل&quot; والذي قد يُؤدي إلى َضعف شديٍد في عضلات معينة.</p><p>- إذا كنت تعاني ِمن ارتفاع َضغط العين مع فقَدان تَدِريجي للبصر (المياه الزرقاء &quot;جلوكوما&quot;).</p><p>- إذا كنت مَصابًا بحساسية (فرط الحساسية) تجاه سوليفيناسين أو أ ٍّي من ُمكونات فيزيكير الأخرى.</p><p>- إذا كنت تَخَضع للغسيل الُكلَوي.</p><p>- إذا كنت تعاني من مرض شديد في الكبد.</p><p>-إذا كنت تعاني من مرض شديد في الكلى أو مرض معتدل في الكبد وتعالج في نفس الوقت بتناول أدوية تقلل من إزالة فيزيكير من الجسم (على سبيل المثال كيتوكونازول). سيقوم الطبيب أو الصيدلي الخاص بك بإخبارك إذا كانت هذه هي الحالة.</p><p>إذا كُنْتَ تُعَانِي أو عَانَيتَ مُسْبَقًا من أيٍّ مِن الحالات السابقة، أَخْبِر طَبِيبَك قَبْل البدء في العِلاج باستخدام فيزيكير.</p><p>تَوَخَّ حَذَرًا خَاصًّا مع فيزيكير</p><p>- إذا كُنْتَ تُوَاجِه مُشْكِلة في إِفْرَاغِ المَثَانَة (= انسداد المثانة)، أو كُنْتَ تُعَاني من صُعُوبَة في التَّبول (مثل تَدَفّق البول في هيئة خيط رفيع). إِنّ مَخَاطِر تَرَاكُم البول في المَثَانة (احتباس البول) أَشَدّ بكثير.</p><p>- إذا كُنْت تُعَانِي مِن انسدادٍ في الجِهَازِ الهَضْمِي (إمساك).</p><p>- إذا كُنْتَ تُعَانِي مِن مَخَاطِر تَبَاطُؤ الجهاز الهضمي (حركة المعدة والامعاء). سَيُخْبِرك طَبِيبُك إذا كَانَت هَذِه هي الحالة.</p><p>- إذا كُنْتَ تُعَاني مِن مَرَضٍ شَدِيدٍ في الكُلَى.</p><p>- إذا كُنْتَ تُعَانِي من مرضٍ مُعْتدل في الكَبِد.</p><p>- إذا كُنْتَ تُعَانِي مِن تَمَزُّق في المعدة (فَتْق حِجَابِيّ) أو حُمُوضَة.</p><p>- إذا كُنْتَ تُعَاني من اضطٍّراب عَصَبِي (اعتلال عصبي مستقلي).</p><p>لا يُمْكِن اسْتِخدام فيزيكير للأطفال والمراهقين أقل من ١٨ سنة.</p><p>أَخْبِر طَبِيبَك إذا كُنْتَ تُعَاني أو عَانَيْت مسبقًا من أيٍّ من الحالات السابقة قَبْل بدء العِلاج باستخدام فيزيكير.</p><p>تمّ الابلاغ عن بعض حالات الوذمة الوعائية (حساسية في الجلد يَنْتُج عَنْها تَوَرّم في النسيج تَحْتَ سَطْحِ الجلد مباشرة) مع انسداد في المسالك الهوائية (صعوبة في التنفس) في بعض المرضى الذين يَتَنَاولون سوليفيناسين سكسينات (فيزيكير). إذا أُصِبْت بوذمة وعائية، فيَجِب أن تَتَوَقّف عن تَنَاوُل سوليفيناسين سكسينات (فيزيكير) فَورًا ويَجِب تَلَقّيك للعلاج و/أو التدابير المناسبة.</p><p>قَبْل البدء في تناول فيزيكير، سيقوم الطبيبُ بِتَقييم ما إذا كان هناك أسبابٌ أُخْرى لِحَاجتك للتبول بشكل مُتَكَرر [مثل هبوط (فشل) القلب (قُصُور بِقُدْرة القلب غير ضَخِّ الدَّم) أو مرض في الكلى].</p><p>إذا كُنْتَ تعاني من عدوى في المسالك البولية، فَسَيَصِف لك طَبِيبُك مُضَادًّا حَيَويًّا (علاجًا لبعض أنواع معينة من العدوى البكتيرية.)</p><p>تَناوُل أدوية أخرى</p><p>يُرجى إِخْبَار الطبيبِ أو الصيدليّ الخاص بِك إذَا كُنْت تَتَناول أو تَنَاوَلت مؤخرًا أيَّة أدوية أخرى بما في ذلك الادوية التي حَصَلْت عليها دُونَ وَصْفَةٍ طِبَّيّة.</p><p>من المهم إخِبَار طَبيِبك خَاصَّة إذَا كُنْتَ تتناول الاتي:</p><p>- أَدْوِية أخرى من مُضَادَّات الكولينيات؛ لأنه قد تَزْدَاد التِّأثيرات والاعراض الجانبية لِكِلا الدَّواءَين.</p><p>- الكولينيات؛ لأنها قَدْ تُقَلّل مِن تَأثير فيزيكير.</p><p>- أَدْوِية مثل ميتوكلوبراميد وسيسابريد والتي تَجْعَل الجهَازِ الهضْمي يَعمَل بِشَكلٍ أَسْرع. فَقَد يُقَلّل فيزيكير من تَأثِيرها.</p><p>- أَدْوية مثل كيتوكونازول وريتونافير ونيلفينافير وإتراكونازول وفيراباميل وديلتيازيم والتي تُقَلّل من مُعَدّل تَحَلّل &quot;فيزيكير&quot; في الجسم.</p><p>- أَدْوية مثل ريفامبيسين وفينيتوين وكاربامازيبين؛ لأنها قَدْ تَزِيد من مُعَدّل تَحَلّل &quot;فيزيكير&quot; في الجسم.</p><p>- أَدْوية مثل البيسفوسفونات والتي قَدْ تُسبب أو تَزِيد من التهاب المَريء.</p><p>تَنَاوُل فيزيكير مع الطعام والشراب</p><p>من الممكن تَنَاوُل فيزيكير مع الطعام أو بدونه، وفقًا لما تُفضله.</p><p>الحَمْل والرَّضَاعَة الطَّبيعية</p><p>يجب أن لا تَتَنَاولي فيزيكير إذا كنتِ حاملا إلا إذَا كانت هناك حاجة ضَرُورِية لذلك.</p><p>لا تَتَناولي فيزيكير أثناء الارضاع؛ لان سوليفيناسين قد يَصِل إلى لَبَن الام.</p><p>استشيري الطبيب أو الصيدلي الخاص بكِ قبل تَنَاوُل هذا الدواء.</p><p>القيادة واستخدام الآلات</p><p>قد يُسَبّب فيزيكير عَدَم وُضُوح الرُّؤية وفي بَعْض الاحْيَان نُعَاسًا أو تَعَبًا. إذا عَانَيت من أيٍّ من هذه الاعراض الجانبية فَلا تَقُم بالقيادة أو استخدام الآلات.</p><p>معلومات هَامَّة حول بعض مكونات فيزيكير</p><p>يَحتوي فيزيكير عَلى سُكّر ال &quot;لاكتوز&quot;. إذا كَان طَبِيبُك قد أَخْبَرك أَنَّك تُعَاني من مَرَضٍ وراثيّ نَادِرٍ مثل عَدَمِ تَحَمّل الجالاكتوز أو نَقْص إِنْزِيم اللاب لاكتاز أو سوء امتصاص الجلوكوز-</p><p>جالاكتوز، فلا يَجِب أن تَتَنَاول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تعليمات الاستخدام السليم</p><p>تَنَاوَل دائمًا فيزيكير بالضبط كما أَخْبَرك طبيبك. إذَا لم تَكُن مُتَأكًّدا، يَجِب عليك مُرَاجَعة الطبيب أو الصيدلي الخاص بِكَ.</p><p>يَجِب ابْتِلاع القرص كاملا مع بعض السوائل. يُمْكن تَنَاوُله مع الطعام أو بدونه وفقًا لما تفضله. لا تَسْحَق الاقراص.</p><p>الجرعة المعتادة هي ٥ ملج يوميًّا ما لم يكن طبيبك قد طَلَب مِنْك تَنَاوُل ١٠ ملج يَوميًّا.</p><p>إذا تَنَاوَلت كمية من فيزيكير أَكْثَر مما يجب</p><p>إذَا تَنَاوَلت كَمّية كبيرة جدًّا من فيزيكير أو إذَا قَامَ طِفْلٌ بتَنَاول فيزيكير بطريق الخطأ، اتصل بالطبيب أو الصيدلي الخاص بِك على الفور.</p><p>تَشْمَل أَعْرَاضُ الجرعة الزائدة: الصَّداع، وجَفَاف الفم، والدوخة، والنعاس، وعدم وضوح الرؤية، وتَخَيل أشياء لا وُجود لها (هلوسة)، والاستثارة الزائدة، ونوبات تَشَنّج، وصُعُوبة في التَّنفس، وارتفاع معدل ضربات القلب، وتراكم البول في المثانة (احتباس البول) وتوسع حَدَقَة العين.</p><p>إذا نَسِيت تَنَاوُل فيزيكير</p><p>إذَا نَسِيت تَنَاوُل جُرْعة في مَوْعِدِها المعتاد، قُمْ بِتَنَاوِلها بِمُجَرّد أن تَتَذَكَّرها، إلا إذا كان مَوْعِد تَنَاوُل الجرعة التالية قَد حَانَ. لا تَتَنَاول أَكْثَر من جُرْعَة واحدة في اليوم. إذَا كَانَ لَدَيك شَكّ، فاستشر دائمًا الطبيب أو الصيدلي الخاص بك.</p><p>إذا تَوَقَّفت عَن تَنَاوُل فيزيكير</p><p>إذَا تَوَقَّفت عن تناول فيزيكير فقد تعود أو تسوء أعراضُ فَرْط نَشَاط المثانة.</p><p>استَشِر طَبِيبَك دائما إذا كُنْتَ تُفَكّر في إِيقَاف العلاج.</p><p>إذا كَانَتْ لديك أسئلة أُخْرى عن استخدام هَذَا الدواء، فاستشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الادوية فَإِنّ فيزيكير لَه أعراض جَانِبِيّة إلا أَنَّها لا تَحْدُث للجميع.</p><p>قَد يَتَسَبَّب فيزيكير في حُدُوثِ مَا يلي:</p><p>أعراض جانبية شائعة جدًّا (يُحْتَمل أن تُصِيبَ أَكْثَر من مريضٍ وَاحِد (١) من بين ١٠ مرضى)</p><p>- جفاف الفم</p><p>أعراض جانبية شائعة (يُحْتَمل أن تُصِيبَ أَكْثَر من مريض واحد (١) بين ١٠٠ مريض وأَقَل من مريضٍ واحد (١) من بين ١٠ مرضى</p><p>- عَدَم وُضُوح الرؤية</p><p>- إِمْسْاك، غَثَيَان، عُسْر هَضْم مَعَ أَعْرَاض مثل امْتِلاء البَطن، أَلَم في البَطْن، تَجَشُّؤ، وحُمُوضَة (عُسْر الهضم)، وشُعُور غير مُرِيحٍ في المعدة.</p><p>أعراض جانبية غير شائعة (يُحْتَمل أن تُصِيبَ أَكْثَر من مريض واحد (١) بين ١٠٠٠ مريض وأَقَلّ من مريضٍ وَاحِد (١) من بين ١٠٠ مريض)</p><p>- عَدْوى المسالكِ البَولية، عَدْوى المثانة.</p><p>- نُعَاس.</p><p>- قُصُور بِحَاسة التَّذوق (اضطرابات التذوق).</p><p>- جَفَاف (تهيج) العينين.</p><p>- جَفَاف الممرات الانفية.</p><p>- جَزر مَعِديّ مَرّيئي (ارتجاع).</p><p>- جَفَاف الحلق.</p><p>- جَفَاف الجلد.</p><p>- صُعوبَة التَّبول.</p><p>- تَعَب.</p><p>- تَرَاكُم السَّوائل في الساقين (وذمة).</p><p>أعراض جانبية نادرة (يُحْتَمل أن تُصِيبَ أَكثَر من مريض واحد (١) بين ١٠٠٠٠ مريض وأقل من مريض واحد (١) من بين ١٠٠٠ مريض)</p><p>- بَقَاء كَمِّية كبيرة من البراز المتصلب في الامعاء الغليظة (انحشار البراز).</p><p>- تَجَمّع البَول في المثانة بِسَبَب عَدَمِ القُدْرة على إِفْراغ المثانة (احتباس البول).</p><p>- دوخة، صُدَاع.</p><p>- قَيء.</p><p>- حَكّة، طَفْح جِلْدِيّ.</p><p>أعراض جانبية نادرة جدًّا (يُحْتَمل أن تُصِيبَ أَقَلّ من مريض واحد (١) بين ١٠٠٠٠ مريض)</p><p>- هلوسة، ارتِبَاك.</p><p>- تَغَيّرات في النَّشاط الكهربائي للقلب (في اختبار رسم القلب)، عدم انتظام ضَرَبَات القلب (أَحَد التَّغيرات بِرَسم القلب والتي تُعْرَف ب&quot;الالتفاف حَولَ النّقْطة&quot;)</p><p>- طفح جلدي تَحسسي (حساسية).</p><p>- حَسَاسية في الجلد يَنْتُج عَنْها تَوَرّم في النِّسيج تَحْتَ سَطْحِ الجلد مباشرة (وذمة وعائية).</p><p>- أعراض جانبية لا يمكن تحديد نسبة حدوثها من البيانات المتاحة</p><p>&bull; قلة الشهية، وارتفاع مستويات البوتاسيوم في الدم التي يمكن أن تسبب عدم انتظام ضَرَبَات القلب</p><p>&bull; زيادة الضغط في العين</p><p>&bull; اضطراب في الصوت</p><p>&bull; اضطراب الكبد</p><p>&bull; ضعف العضلات</p><p>&bull; اضطراب الكلى</p><p>إذَا أَصبَح أَيّ من الاعراض الجانبية خطيرا، أو إذَا لاحَظْت أَيَّة أعراض جانبية غير المدرجة في هذه النَّشرة، يُرجى إخبار الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متَنَاول ورؤية الاطفال.</p><p>يُحفَظ في درجِة حرارة أقل من ٣٠ درجة مئوية.</p><p>لا تستخدم فيزيكير بعد انتهاء تاريخ الصلاحية المدون على العبوة بعد الكلمة EXP تاريخ الانتهاء يُشِيْر إلى اليوم الاخير في ذلك الشهر..</p><p>يَجِب عَدَم التخلص من الادوية عن طَرِيق إلْقَائها في مياه الصرف أو مع المخلفات المنزلية.</p><p>استفسر من الصيدلي الخاص بكِ عن كيفية التخلص من الادوية التي لم تَعُد بِحَاجَة إليها. ستساعد هذه الاجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي: سوليفيناسين سكسينات ٥ ملج</p><p>&bull; المُكَوّنات الاخرى هي: نِشا الذرة، لاكتوز أحادي الهيدرات، هيبروميللوز، ستيرات الماغنسيوم، أوبادري اصفر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص فيزيكير ٥ ملج هي أقراص مغلفة دائرية ذات لون أَصْفر فَاتح منقوش عليها233 SJ من احد الوجهين تحتوي العبوة على ٣٠ قرصًا مغلفا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مصنع ساجا للصناعات الدوائية</p><p>الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة</p><p>جدة- المملكة العربية السعودية</p><p>بترخيص من شركة أستيلاس فارما المحدودة</p><p>طوكيو &ndash; اليابان.</p><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية</strong><br /><strong><strong>&bull; </strong></strong><strong>المملكة العربية السعودية</strong><br />- المركز الوطني للتيقظ والسامة الدوائية<br />- فاكس: 7662-205-11-966+<br />- مركز اتصالات الهيئة العامة للغذاء والدواء السعودية : 19999<br />&nbsp;npc.drug@sfda.gov.sa :- البريد الإلكتروني<br />&nbsp;https://ade.sfda.gov.sa :- الموقع الإلكتروني<br /><strong><strong>&bull; </strong></strong><strong>دول الخليج الأخرى/ الدول الأخرى</strong><br />- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p><p dir="RTL"><strong>الإمارات العربية المتحدة</strong><br />قسم اليقظة الدوائية و الوسائل الطبية<br />صندوق بريد: 1853<br />80011111 :هاتفٍ<br />pv@mohap.gov.ae :أيميل<br />إدارة الدواءً<br />وزارة الصحة ووقاية المجتمع<br />دبي - الإمارات العربية المتحدة<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو / 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vesicare® 10 mg, film-coated tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vesicare 10 mg film-coated tablet:
Each tablet contains 10 mg solifenacin succinate, corresponding to 7.5 mg
solifenacin.
Excipients: lactose monohydrate (102.5 mg)
For a full list of excipients, see Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.
Vesicare 10 mg tablets are round, light -pink tablets film coated tablet, Coded by SJ
232 on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic treatment of urge incontinence and/or increased urinary frequency<br />and urgency as may occur in patients with overactive bladder syndrome.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults, including the elderly<br />The recommended dose is 5 mg solifenacin succinate once daily. If needed, the dose<br />may be increased to 10 mg solifenacin succinate once daily.<br />Children and adolescents<br />Safety and effectiveness in children have not yet been established. Therefore,<br />Vesicare should not be used in children.<br />Special populations<br />Patients with renal impairment<br />No dose adjustment is necessary for patients with mild to moderate renal<br />impairment (creatinine clearance &gt; 30 ml/min). Patients with severe renal<br />impairment (creatinine clearance 30 ml/min) should be treated with caution and<br />receive no more than 5 mg once daily (see Section 5.2).<br />Patients with hepatic impairment<br />No dose adjustment is necessary for patients with mild hepatic impairment. Patients<br />with moderate hepatic impairment (Child-Pugh score of 7 to 9) should be treated<br />with caution and receive no more than 5 mg once daily (see Section 5.2).<br />Potent inhibitors of cytochrome P450 3A4<br />The maximum dose of Vesicare should be limited to 5 mg when treated<br />simultaneously with ketoconazole or therapeutic doses of other potent CYP3A4-<br />inhibitors e.g. ritonavir, nelfinavir, itraconazole (see Section 4.5).<br />Method of administration<br />Vesicare should be taken orally and should be swallowed whole with liquids. It can<br />be taken with or without food<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solifenacin is contraindicated in patients with urinary retention, severe gastrointestinal condition (including toxic megacolon), myasthenia gravis or narrow-angle
glaucoma and in patients at risk for these conditions.
- Patients hypersensitive to the active substance or to any of the excipients.
- Patients undergoing haemodialysis (see Section 5.2).
- Patients with severe hepatic impairment (see Section 5.2).
- Patients with severe renal impairment or moderate hepatic impairment and who
are on treatment with a potent CYP3A4 inhibitor, e.g. ketoconazole (see Section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Other causes of frequent urination (heart failure or renal disease) should be assessed<br />before treatment with Vesicare. If urinary tract infection is present, an appropriate<br />antibacterial therapy should be started.<br />Vesicare should be used with caution in patients with:<br />- clinically significant bladder outflow obstruction at risk of urinary retention.<br />- gastrointestinal obstructive disorders.<br />- risk of decreased gastrointestinal motility.<br />- severe renal impairment (creatinine clearance 30 ml/min; see Section 4.2 and<br />5.2), and doses should not exceed 5 mg for these patients.<br />- moderate hepatic impairment (Child-Pugh score of 7 to 9; see Section 4.2 and 5.2),<br />and doses should not exceed 5 mg for these patients.<br />- concomitant use of a potent CYP3A4 inhibitor, e.g. ketoconazole (see 4.2 and 4.5).<br />- hiatus hernia/gastro-oesophagal reflux and/or who are concurrently taking<br />medicinal products (such as bisphosphonates) that can cause or exacerbate<br />oesophagitis.<br />Autonomic neuropathy.<br />QT prolongation and Torsade de Pointes have been observed in patients with risk factors,<br />such as pre-existing long QT syndrome and hypokalaemia.<br />Safety and efficacy have not yet been established in patients with a neurogenic<br />cause for detrusor overactivity.<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase<br />deficiency or glucose-galactose malabsorption should not take this medicinal<br />product.<br />Angioedema with airway obstruction has been reported in some patients on<br />solifenacin succinate. If angioedema occurs, solifenacin succinate should be<br />discontinued and appropriate therapy and/or measures should be taken.<br />Anaphylactic reaction has been reported in some patients treated with solifenacin<br />succinate. In patients who develop anaphylactic reactions, solifenacin succinate<br />should be discontinued and appropriate therapy and/or measures should be taken.<br />The maximum effect of Vesicare can be determined after 4 weeks at the earliest.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacological interactions<br />Concomitant medication with other medicinal products with anticholinergic<br />properties may result in more pronounced therapeutic effects and undesirable<br />effects. An interval of approximately one week should be allowed after stopping<br />treatment with Vesicare, before commencing other anticholinergic therapy. The<br />therapeutic effect of solifenacin may be reduced by concomitant administration of<br />cholinergic receptor agonists.<br />Solifenacin can reduce the effect of medicinal products that stimulate the motility of<br />the gastro-intestinal tract, such as metoclopramide and cisapride.<br />Pharmacokinetic interactions<br />In vitro studies have demonstrated that at therapeutic concentrations, solifenacin<br />does not inhibit CYP1A1/2, 2C9, 2C19, 2D6, or 3A4 derived from human liver<br />microsomes. Therefore, solifenacin is unlikely to alter the clearance of drugs<br />metabolised by these CYP enzymes.<br />Effect of other medicinal products on the pharmacokinetics of solifenacin<br />Solifenacin is metabolised by CYP3A4. Simultaneous administration of ketoconazole<br />(200 mg/day), a potent CYP3A4 inhibitor, resulted in a two-fold increase of the AUC<br />of solifenacin, while ketoconazole at a dose of 400 mg/day resulted in a three-fold<br />increase of the AUC of solifenacin. Therefore, the maximum dose of Vesicare should<br />be restricted to 5 mg, when used simultaneously with ketoconazole or therapeutic<br />doses of other potent CYP3A4 inhibitors (e.g. ritonavir, nelfinavir, itraconazole) (see<br />Section 4.2).<br />Simultaneous treatment of solifenacin and a potent CYP3A4 inhibitor is contraindicated in patients with severe renal impairment or moderate hepatic impairment.<br />The effects of enzyme induction on the pharmacokinetics of solifenacin and its<br />metabolites have not been studied as well as the effect of higher affinity CYP3A4<br />substrates on solifenacin exposure. Since solifenacin is metabolised by CYP3A4,<br />pharmacokinetic interactions are possible with other CYP3A4 substrates with higher<br />affinity (e.g. verapamil, diltiazem) and CYP3A4 inducers (e.g. rifampicin, phenytoin,<br />carbamazepin).<br />Effect of solifenacin on the pharmacokinetics of other medicinal products<br />Oral Contraceptives<br />Intake of Vesicare showed no pharmacokinetic interaction of solifenacin on<br />combined oral contraceptives (ethinylestradiol/levonorgestrel).<br />Warfarin<br />Intake of Vesicare did not alter the pharmacokinetics of R-warfarin or S-warfarin or<br />their effect on prothrombin time.<br />Digoxin<br />Intake of Vesicare showed no effect on the pharmacokinetics of digoxin.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />No clinical data are available from women who became pregnant while taking<br />solifenacin. Animal studies do not indicate direct harmful effects on fertility,<br />embryonal / foetal development or parturition (see Section 5.3). The potential risk<br />for humans is unknown. Caution should be exercised when prescribing to pregnant<br />women.<br />Lactation<br />No data on the excretion of solifenacin in human milk are available. In mice,<br />solifenacin and/or its metabolites was excreted in milk, and caused a dose<br />dependent failure to thrive in neonatal mice (see Section 5.3). The use of Vesicare<br />should therefore be avoided during breast-feeding.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since solifenacin, like other anticholinergics may cause blurred vision, and,<br />uncommonly, somnolence and fatigue (see section 4.8. undesirable effects), the<br />ability to drive and use machines may be negatively affected.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong><em>Summary of the safety profile</em></strong></p><p>Due to the pharmacological effect of solifenacin, Vesicare may cause anticholinergic undesirable effects of (in general) mild or moderate severity. The frequency of anticholinergic undesirable effects is dose related.</p><p>The most commonly reported adverse reaction with Vesicare was dry mouth. It occurred in 11% of patients treated with 5 mg once daily, in 22% of patients treated</p><p>&nbsp;</p><p>with 10 mg once daily and in 4% of placebo-treated patients. The severity of dry mouth was generally mild and did only occasionally lead to discontinuation of treatment. In general, medicinal product compliance was very high (approximately 99%) and approximately 90% of the patients treated with Vesicare completed the full study period of 12 weeks treatment.</p><p><em>b.&nbsp;&nbsp;&nbsp; </em><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image2.png" o:spid="_x0000_s1047" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:128.6pt;
 margin-top:51.55pt;width:4.5pt;height:6pt;z-index:-252830720;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/asus/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/asus/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />Tabulated summary of adverse reactions</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri'><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group
 id="_x0000_s1036" style='width:278.25pt;height:.75pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="5565,15">
 <v:rect id="_x0000_s1037" style='position:absolute;width:29;height:15'
  fillcolor="#9f9f9f" stroked="f"/>
 <v:line id="_x0000_s1038" style='position:absolute' from="29,7" to="1728,7"
  strokecolor="#9f9f9f" strokeweight=".72pt"/>
 <v:rect id="_x0000_s1039" style='position:absolute;left:1728;width:44;
  height:15' fillcolor="#9f9f9f" stroked="f"/>
 <v:line id="_x0000_s1040" style='position:absolute' from="1772,7" to="2763,7"
  strokecolor="#9f9f9f" strokeweight=".72pt"/>
 <v:rect id="_x0000_s1041" style='position:absolute;left:2763;width:44;
  height:15' fillcolor="#9f9f9f" stroked="f"/>
 <v:line id="_x0000_s1042" style='position:absolute' from="2807,7" to="4124,7"
  strokecolor="#9f9f9f" strokeweight=".72pt"/>
 <v:rect id="_x0000_s1043" style='position:absolute;left:4124;width:44;
  height:15' fillcolor="#9f9f9f" stroked="f"/>
 <v:line id="_x0000_s1044" style='position:absolute' from="4167,7" to="5565,7"
  strokecolor="#9f9f9f" strokeweight=".72pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="372" height="2" src="file:///C:/Users/asus/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:278.25pt;height:.75pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>MedDRA system&nbsp;&nbsp;&nbsp;&nbsp; organ class</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p><p>1/10</p></td><td style="vertical-align:top"><p>Common</p><p>&gt;1/100,</p><p>&lt;1/10</p></td><td style="vertical-align:top"><p>Uncommon</p><p>&gt;1/1000,</p><p>&lt;1/100</p></td><td style="vertical-align:top"><p>Rare</p><p>&gt; 1/10000,</p><p>&lt;1/1000</p></td><td style="vertical-align:top"><p>Very rare</p><p>&lt;1/10,000</p></td><td style="vertical-align:top"><p>Not&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; known (cannot&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; be</p><p>estimated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; from the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; available</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>data)</p></td></tr><tr><td style="vertical-align:top"><p>Infections&nbsp;&nbsp;&nbsp; and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary tract infection Cystitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction*</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism&nbsp;&nbsp;&nbsp; &amp; nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased appetite* Hyperkalaemia*</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hallucinations*, Confusional state*</p></td><td style="vertical-align:top"><p>Delirium*</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Somnolence Dysgeusia</p></td><td style="vertical-align:top"><p>Dizziness*, Headache*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blurred vision</p></td><td style="vertical-align:top"><p>Dry eyes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Glaucoma*</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Torsade de Pointes*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Electrocardiogra m QT prolonged*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Atrial fibrillation*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia*</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nasal</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysphonia*</p></td></tr><tr><td style="vertical-align:top"><p>thoracic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>mediastinal</p></td><td style="vertical-align:top"><p>dryness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri'><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group
 id="_x0000_s1027" style='width:278.25pt;height:.75pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="5565,15">
 <v:rect id="_x0000_s1028" style='position:absolute;width:29;height:15'
  fillcolor="#9f9f9f" stroked="f"/>
 <v:line id="_x0000_s1029" style='position:absolute' from="29,7" to="1728,7"
  strokecolor="#9f9f9f" strokeweight=".72pt"/>
 <v:rect id="_x0000_s1030" style='position:absolute;left:1728;width:44;
  height:15' fillcolor="#9f9f9f" stroked="f"/>
 <v:line id="_x0000_s1031" style='position:absolute' from="1772,7" to="2763,7"
  strokecolor="#9f9f9f" strokeweight=".72pt"/>
 <v:rect id="_x0000_s1032" style='position:absolute;left:2763;width:44;
  height:15' fillcolor="#9f9f9f" stroked="f"/>
 <v:line id="_x0000_s1033" style='position:absolute' from="2807,7" to="4124,7"
  strokecolor="#9f9f9f" strokeweight=".72pt"/>
 <v:rect id="_x0000_s1034" style='position:absolute;left:4124;width:44;
  height:15' fillcolor="#9f9f9f" stroked="f"/>
 <v:line id="_x0000_s1035" style='position:absolute' from="4167,7" to="5565,7"
  strokecolor="#9f9f9f" strokeweight=".72pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="372" height="2" src="file:///C:/Users/asus/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri'><v:shape id="_x0000_i1026"
 type="#_x0000_t75" style='width:278.25pt;height:.75pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Constipatio n</p><p>Nausea Dyspepsia Abdominal pain</p></td><td style="vertical-align:top"><p>Gastro- oesophageal reflux diseases</p><p>Dry throat</p></td><td style="vertical-align:top"><p>Colonic obstruction Faecal impaction, Vomiting*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ileus*</p><p><strong>&nbsp;</strong></p><p>Abdominal discomfort*</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver disorder*</p><p><strong>&nbsp;</strong></p><p>Liver function test abnormal*</p></td></tr><tr><td style="vertical-align:top"><p>Skin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>Pruritus*, Rash*,</p></td><td style="vertical-align:top"><p>Erythema multiforma*, Urticaria*, Angioedema*</p></td><td style="vertical-align:top"><p>Exfoliative dermatitis*</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscular weakness*</p></td></tr><tr><td style="vertical-align:top"><p>Renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Difficulty&nbsp;&nbsp;&nbsp; in micturition</p></td><td style="vertical-align:top"><p>Urinary retention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal impairment*</p></td></tr><tr><td style="vertical-align:top"><p>General disorders&nbsp;&nbsp;&nbsp;&nbsp; and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue Peripheral oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*&nbsp; observed post-marketing</p><p>QT prolongation and Torsade de Pointes have been reported in association with solifenacin use in worldwide post marketing experience. Because these spontaneously reported events are from the worldwide post marketing experience, the frequency of events and the role of solifenacin in their causation cannot be reliably determined.</p><p>--To report any side effect (s)</p><p>&nbsp; &nbsp;&nbsp;<!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t202"
  coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1045" type="#_x0000_t202" style='position:absolute;
  left:0;text-align:left;margin-left:84.4pt;margin-top:27.45pt;width:426.7pt;
  height:90.5pt;text-indent:0;z-index:-251653120;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page' filled="f"
  strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.1pt;margin-right:0in;margin-bottom:
     0in;margin-left:11.85pt;margin-bottom:.0001pt;text-indent:-6.55pt;
     mso-list:l2 level1 lfo2;tab-stops:11.9pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>The National
     Pharmacovigilance Centre<span style='letter-spacing:-.05pt'> </span>(NPC):<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:11.85pt;text-indent:-6.55pt;
     mso-list:l2 level1 lfo2;tab-stops:11.9pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>SFDA Call Center:<span
     style='letter-spacing:-.1pt'> </span>19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:11.85pt;text-indent:-6.55pt;
     mso-list:l2 level1 lfo2;tab-stops:11.9pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>E-mail:<span
     style='letter-spacing:-.1pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:11.85pt;text-indent:-6.55pt;
     mso-list:l2 level1 lfo2;tab-stops:11.9pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:<span
     style='letter-spacing:-.1pt'> </span>https://ade.sfda.gov.sa<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong style="text-align:unset">Saudi Arabia:</strong></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="574" height="125" alt="Text Box: -	The National Pharmacovigilance Centre (NPC):
-	SFDA Call Center: 19999
-	E-mail: npc.drug@sfda.gov.sa
-	Website: https://ade.sfda.gov.sa
" src="file:///C:/Users/asus/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states /other countries</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1026"
 type="#_x0000_t202" style='width:390.7pt;height:17.2pt;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001'
 filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:1.2pt;margin-right:0in;margin-bottom:
    0in;margin-left:5.35pt;margin-bottom:.0001pt'>-Please contact the relevant
    competent authority.<o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="526" height="27" alt="Text Box: -Please contact the relevant competent authority." src="file:///C:/Users/asus/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1027"
 type="#_x0000_t75" style='width:390.7pt;height:17.2pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>&bull;&nbsp; <strong>United Arab Emirates</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1046" type="#_x0000_t202" style='position:absolute;margin-left:120.5pt;
  margin-top:18.5pt;width:390.7pt;height:100pt;z-index:-251651072;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:1.05pt;margin-right:2.3in;
     margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt;text-indent:
     -2.65pt;line-height:106%'>-Pharmacovigilance &amp; Medical Device section
     P.O.Box: 1853<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.1pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.35pt;margin-bottom:.0001pt'>Tel:<span style='letter-spacing:
     -.2pt'> </span>80011111<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.95pt;margin-right:256.6pt;
     margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt;line-height:
     106%'>Email : <a href="mailto:pv@mohap.gov.ae"><span style='color:windowtext;
     text-decoration:none;text-underline:none'>pv@mohap.gov.ae</span></a> Drug
     Department<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.1pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.35pt;margin-bottom:.0001pt'>Ministry of Health &amp;
     Prevention Dubai - UAE<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="526" height="138" alt="Text Box: -Pharmacovigilance &amp; Medical Device section P.O.Box: 1853
Tel: 80011111
Email : pv@mohap.gov.ae Drug Department
Ministry of Health &amp; Prevention Dubai - UAE
" src="file:///C:/Users/asus/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Overdosage with solifenacin succinate can potentially result in severe anticholinergic<br />effects. The highest dose of solifenacin succinate accidentally given to a single<br />patient was 280 mg in a 5 hour period, resulting in mental status changes not<br />requiring hospitalization.<br />Treatment<br />In the event of overdose with solifenacin succinate the patient should be treated<br />with activated charcoal. Gastric lavage is useful if performed within 1 hour, but<br />vomiting should not be induced.<br />As for other anticholinergics, symptoms can be treated as follows:<br />- Severe central anticholinergic effects such as hallucinations or pronounced<br />excitation: treat with physostigmine or carbachol.<br />- Convulsions or pronounced excitation: treat with benzodiazepines.<br />- Respiratory insufficiency: treat with artificial respiration.<br />- Tachycardia: treat with beta-blockers.<br />- Urinary retention: treat with catheterisation.<br />- Mydriasis: treat with pilocarpine eye drops and/or place patient in dark room.<br />As with other antimuscarinics, in case of overdosing, specific attention should be<br />paid to patients with known risk for QT-prolongation (i.e. hypokalaemia, bradycardia<br />and concurrent administration of medicinal products known to prolong QT-interval)<br />and relevant pre-existing cardiac diseases (i.e. myocardial ischaemia, arrhythmia,<br />congestive heart failure).<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Urinary antispasmodics, ATC code: G04B D08.</p><p>Mechanism of action:</p><p>Solifenacin is a competitive, specific cholinergic-receptor antagonist.</p><p>The urinary bladder is innervated by parasympathetic cholinergic nerves. Acetylcholine contracts the detrusor smooth muscle through muscarinic receptors of which the M3 subtype is predominantly involved. In vitro and in vivo pharmacological studies indicate that solifenacin is a competitive inhibitor of the muscarinic M3 subtype receptor. In addition, solifenacin showed to be a specific antagonist for muscarinic receptors by displaying low or no affinity for various other receptors and ion channels tested.</p><p>Pharmacodynamic effects:</p><p>Treatment with Vesicare in doses of 5 mg and 10 mg daily was studied in several double blind, randomised, controlled clinical trials in men and women with overactive bladder.</p><p>&nbsp;</p><p>As shown in the table below, both the 5 mg and 10 mg doses of Vesicare produced statistically significant improvements in the primary and secondary endpoints compared with placebo. Efficacy was observed within one week of starting&nbsp; treatment and stabilised over a period of 12 weeks. A long-term open label study demonstrated that efficacy was maintained for at least 12 months. After 12 weeks of treatment, approximately 50% of patients suffering from incontinence before</p><p>&nbsp;</p><p>treatment were free of incontinence episodes, and in addition 35% of patients achieved a micturition frequency of less than 8 micturitions per day. Treatment of the symptoms of overactive bladder also results in a benefit on a number of Quality of Life measures, such as general health perception, incontinence impact, role limitations, physical limitations, social limitations, emotions, symptom severity, severity measures and sleep/energy.</p><p><!--[if gte vml 1]><v:group id="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;margin-left:85.95pt;
 margin-top:29.85pt;width:170.35pt;height:.75pt;z-index:251666432;
 mso-position-horizontal-relative:page' coordorigin="1719,597" coordsize="3407,15">
 <v:rect id="_x0000_s1027" style='position:absolute;left:1718;top:596;width:29;
  height:15' fillcolor="#9f9f9f" stroked="f"/>
 <v:line id="_x0000_s1028" style='position:absolute' from="1748,604" to="5082,604"
  strokecolor="#9f9f9f" strokeweight=".72pt"/>
 <v:rect id="_x0000_s1029" style='position:absolute;left:5081;top:596;width:44;
  height:15' fillcolor="#9f9f9f" stroked="f"/>
 <w:wrap anchorx="page"/>
</v:group><![endif]--><img width="227" height="2" src="file:///C:/Users/asus/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><em>Results (pooled data) of four controlled Phase 3 studies with a treatment duration of 12 weeks</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Vesicare 5 mg o.d.</strong></p></td><td style="vertical-align:top"><p><strong>Vesicare 10 mg o.d.</strong></p></td><td style="vertical-align:top"><p><strong>Tolterodine 2 mg b.i.d.</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>No. of micturitions/24 h</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline</p><p>Mean reduction from baseline</p><p>% change from baseline n</p><p>p-value*</p></td><td style="vertical-align:top"><p>11.9</p><p>1.4</p><p>(12%)</p><p>1138</p></td><td style="vertical-align:top"><p>12.1</p><p>2.3</p><p>(19%)</p><p>552</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>11.9</p><p>2.7</p><p>(23%)</p><p>1158</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>12.1</p><p>1.9</p><p>(16%)</p><p>250</p><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p><strong>No. of urgency episodes/24 h</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline</p><p>Mean reduction from baseline</p><p>% change from baseline n</p><p>p-value*</p></td><td style="vertical-align:top"><p>6.3</p><p>2.0</p><p>(32%)</p><p>1124</p></td><td style="vertical-align:top"><p>5.9</p><p>2.9</p><p>(49%)</p><p>548</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>6.2</p><p>3.4</p><p>(55%)</p><p>1151</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>5.4</p><p>2.1</p><p>(39%)</p><p>250</p><p>0.031</p></td></tr><tr><td style="vertical-align:top"><p><strong>No. of incontinence episodes/24 h</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline</p><p>Mean reduction from baseline</p><p>% change from baseline n</p><p>p-value*</p></td><td style="vertical-align:top"><p>2.9</p><p>1.1</p><p>(38%)</p><p>781</p></td><td style="vertical-align:top"><p>2.6</p><p>1.5</p><p>(58%)</p><p>314</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>2.9</p><p>1.8</p><p>(62%)</p><p>778</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>2.3</p><p>1.1</p><p>(48%)</p><p>157</p><p>0.009</p></td></tr><tr><td style="vertical-align:top"><p><strong>No. of nocturia episodes/24 h</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline</p><p>Mean reduction from baseline</p><p>% change from baseline n</p><p>p-value*</p></td><td style="vertical-align:top"><p>1.8</p><p>0.4</p><p>(22%)</p><p>1005</p></td><td style="vertical-align:top"><p>2.0</p><p>0.6</p><p>(30%)</p><p>494</p><p>0.025</p></td><td style="vertical-align:top"><p>1.8</p><p>0.6</p><p>(33%)</p><p>1035</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>1.9</p><p>0.5</p><p>(26%)</p><p>232</p><p>0.199</p></td></tr><tr><td style="vertical-align:top"><p><strong>Volume voided/micturition</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline</p><p>Mean increase from baseline</p><p>% change from baseline n</p><p>p-value*</p></td><td style="vertical-align:top"><p>166 ml</p><p>9 ml</p><p>(5%)</p><p>1135</p></td><td style="vertical-align:top"><p>146 ml</p><p>32 ml</p><p>(21%)</p><p>552</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>163 ml</p><p>43 ml</p><p>(26%)</p><p>1156</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>147 ml</p><p>24 ml</p><p>(16%)</p><p>250</p><p>&lt;0.001</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>No. of pads/24 h</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline</p><p>Mean reduction from baseline</p><p>% change from baseline n</p><p>p-value*</p></td><td style="vertical-align:top"><p>3.0</p><p>0.8</p><p>(27%)</p><p>238</p></td><td style="vertical-align:top"><p>2.8</p><p>1.3</p><p>(46%)</p><p>236</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>2.7</p><p>1.3</p><p>(48%)</p><p>242</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>2.7</p><p>1.0</p><p>(37%)</p><p>250</p><p>0.010</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><u>Note:</u></p><p>&bull;&nbsp; In 4 of the pivotal studies, Vesicare 10 mg and placebo were used. In 2 out of the 4 studies also Vesicare 5 mg was used and one of the studies included tolterodine 2&nbsp; mg bid.</p><p>&bull;&nbsp; Not all parameters and treatment groups were evaluated in each individual study. Therefore, the numbers of patients listed may deviate per parameter and treatment group.</p><p>&bull;&nbsp; * P-value for the pair wise comparison to placebo</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />After intake of Vesicare tablets, maximum solifenacin plasma concentrations<br />(Cmax) are reached after 3 to 8 hours. The tmax is independent of the dose. The<br />Cmax and area under the curve (AUC) increase in proportion to the dose between<br />5 to 40 mg. Absolute bioavailability is approximately 90%.<br />Food intake does not affect the Cmax and AUC of solifenacin.<br />Distribution<br />The apparent volume of distribution of solifenacin following intravenous<br />administration is about 600 L. Solifenacin is to a great extent (approximately<br />98%) bound to plasma proteins, primarily &alpha;1-acid glycoprotein.<br />Biotransformation<br />Solifenacin is extensively metabolised by the liver, primarily by cytochrome P450<br />3A4 (CYP3A4). However, alternative metabolic pathways exist, that can<br />contribute to the metabolism of solifenacin. The systemic clearance of<br />solifenacin is about 9.5 L/h and the terminal half life of solifenacin is 45 - 68<br />hours. After oral dosing, one pharmacologically active (4R-hydroxy solifenacin)<br />and three inactive metabolites (N-glucuronide, N-oxide and 4R-hydroxy-N-oxide<br />of solifenacin) have been identified in plasma in addition to solifenacin.<br />Elimination<br />After a single administration of 10 mg [14C-labelled]-solifenacin, about 70% of the<br />radioactivity was detected in urine and 23% in faeces over 26 days. In urine,<br />approximately 11% of the radioactivity is recovered as unchanged active<br />substance; about 18% as the N-oxide metabolite, 9% as the 4R-hydroxy-N-oxide<br />metabolite and 8% as the 4R-hydroxy metabolite (active metabolite).<br />Linearity/non-linearity<br />Pharmacokinetics are linear in the therapeutic dose range.<br />Other special populations<br />Elderly<br />No dosage adjustment based on patient age is required. Studies in elderly have<br />shown that the exposure to solifenacin, expressed as the AUC, after<br />administration of solifenacin succinate (5 mg and 10 mg once daily) was similar in<br />healthy elderly subjects (aged 65 through 80 years) and healthy young subjects<br />(aged less than 55 years). The mean rate of absorption expressed as tmax was<br />slightly slower in the elderly and the terminal half-life was approximately 20%<br />longer in elderly subjects. These modest differences were considered not<br />clinically significant.<br />The pharmacokinetics of solifenacin have not been established in children and<br />adolescents.<br />Gender<br />The pharmacokinetics of solifenacin are not influenced by gender.<br />Race<br />The pharmacokinetics of solifenacin are not influenced by race.<br />Renal impairment<br />The AUC and Cmax of solifenacin in mild and moderate renally impaired patients,<br />was not significantly different from that found in healthy volunteers. In patients<br />with severe renal impairment (creatinine clearance &le; 30 ml/min) exposure to<br />solifenacin was significantly greater than in the controls with increases in Cmax of<br />about 30%, AUC of more than 100% and t&frac12; of more than 60%. A statistically<br />significant relationship was observed between creatinine clearance and<br />solifenacin clearance.<br />Pharmacokinetics in patients undergoing haemodialysis have not been studied.<br />Hepatic impairment<br />In patients with moderate hepatic impairment (Child-Pugh score of 7 to 9) the<br />Cmax is not affected, AUC increased with 60% and t&frac12; doubled. Pharmacokinetics<br />of solifenacin in patients with severe hepatic impairment have not been studied.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, fertility, embryofetal development, genotoxicity, and<br />carcinogenic potential. In the pre- and postnatal development study in mice, solifenacin<br />treatment of the mother during lactation caused dose-dependent lower postpartum survival<br />rate, decreased pup weight and slower physical development at clinically relevant levels.<br />Dose related increased mortality without preceding clinical signs occurred in juvenile mice<br />treated from day 10 or 21 after birth with doses that achieved a pharmacological effect and<br />both groups had higher mortality compared to adult mice. In juvenile mice treated from<br />postnatal day 10, plasma exposure was higher than in adult mice; from postnatal day 21<br />onwards, the systemic exposure was comparable to adult mice. The clinical implications of<br />the increased mortality in juvenile mice are not known.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maize starch<br />Lactose monohydrate<br />Hypromellose<br />Magnesium stearate<br />Opadry pink (03F14895)<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                48 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vesicare film coated tablets are supplied in PVC.PVDC/ALU blister<br />Packs of 30 tablets.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited
Jeddah – Saudi Arabia
Under license from
ASTELLAS PHARMA INC
Tokyo-Japan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July/ 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>